||Etodolac inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. Et
||Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and in
||Adapalene is a dual RAR and RXR agonist, utilized in the treatment of skin conditions.
||TTNPB, a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.
||Acitretin is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.
||Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. Isotretin
||Fenretinide is an orally-active synthetic retinoid derivative with potential antineoplastic and chemopreventive activities.
||AR7 is a retinoic acid receptor α (RARα) antagonist.
||Bexarotene is a retinoid analogue that is used to treat the skin manifestations of cutaneous T cell lymphoma (CTCL).
||Tamibarotene is an orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.
||Tazarotene is a synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abn
||Etretinate is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. It activates retinoid receptors, causing an induction of cell diffe
||CD437 is a specifc Retinoic Acid Receptor γ (RARγ) agonist.
||Palovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
||WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs, IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).
||AM580 is a retinoic acid receptor agonist that is selective for RARα( IC50 : 8 nM )
||R-flurbiprofen is the non-cyclooxygenase inhibiting R-enantiomer of the non-steroidal anti-inflammatory drug flurbiprofen, which was assessed as a remedy for Alzheimer's disease.
||Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as RXR and RAR.
||AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).
||Magnolol is a dual agonist of RXRα( EC50=10.4 μM) and PPARγ(EC50=17.7 μM). It blocks TNF-α-induced NF-KB activation.
||AGN 194310 (VTP-194310) is retinioic acid receptors (RARs) pan-antagonist. The Kd values of 3 nM, 2 nM, 5 nM for RARα, RARβ, RARγ, respectively.
||BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 also could prevent retinoic acid-induced differentiation. BMS493 increases nuclear corepressor interaction wit
||CD2665 is an antagonist of RAR-beta/gamma (Ki: 110 nM and 306 nM for RARγ and RARβ).
||CD3254 a selective agonist of retinoid-X-receptor (RXR).
||Ch55 is a potent inducer of the differentiation of HL60 cells (EC50: 200 nM). Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 shows a low affinity for cellular r
||LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human pol
||PA452 is a retinoic X receptor (RXR) specific antagonist. PA452 suppresses the effect of Retinoic acid (RA) on Th1/Th2 development.
||LG-100064 is an agonist of retinoid-X-receptor (RXR)(EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ)